Nasal Drug Delivery | Development and Evaluation of Nasal Formulation

Basavaraj Nanjwade (u. a.)

ISBN 10: 384842438X / ISBN 13: 9783848424382

Published by LAP LAMBERT Academic Publishing, 2012

About this Item

Nasal Drug Delivery | Development and Evaluation of Nasal Formulation | Basavaraj Nanjwade (u. a.) | Taschenbuch | 168 S. | Englisch | 2012 | LAP LAMBERT Academic Publishing | EAN 9783848424382 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Seller Inventory # 106495804

Bibliographic Details

• Title: Nasal Drug Delivery | Development and Evaluation of Nasal Formulation
• Publisher: LAP LAMBERT Academic Publishing
• Publication Date: 2012
• Language: English
• ISBN 10: 384842438X
• ISBN 13: 9783848424382
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 11D millimeters 220 millimeters width by 150 millimeters height by 11 millimeters depth
• Weight: 268 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide – a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation.

About the Author

Dr. Basavaraj K. Nanjwade has completed his Ph.D from Rajiv Gandhi University of Health Sciences Karnataka, Bangalore. He is the Director of KLE Society’s College of Pharmacy, Nipani, Karnataka, India. He has published 71 papers in reputed national and international journals and 12 Patents. He guided 19 M.Pharm and 7 Ph. D students.